ArticleAnnals of the rheumatic diseases2022

Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere

Nicola Potere et al.PubMed ↗Publisher ↗

No numbers read from the abstract.